vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and RXO, Inc. (RXO). Click either name above to swap in a different company.
RXO, Inc. is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.2× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -3.1%, a 20.1% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -11.9%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $-9.0M). Over the past eight quarters, RXO, Inc.'s revenue compounded faster (26.8% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
RXO, Inc. is a leading transportation and logistics solutions provider headquartered in the United States. Its core service portfolio includes freight brokerage, last-mile delivery for heavy and bulky goods, managed transportation services, and end-to-end supply chain optimization support, primarily catering to clients across the North American manufacturing, retail, and e-commerce segments.
JAZZ vs RXO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.5B |
| Net Profit | $203.5M | $-46.0M |
| Gross Margin | — | — |
| Operating Margin | 21.2% | -2.9% |
| Net Margin | 17.0% | -3.1% |
| Revenue YoY | 10.1% | -11.9% |
| Net Profit YoY | 6.5% | -84.0% |
| EPS (diluted) | $3.34 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $897.8M | $1.4B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $902.0M | $913.0M |
| Q4 25 | $203.5M | $-46.0M | ||
| Q3 25 | $251.4M | $-14.0M | ||
| Q2 25 | $-718.5M | $-9.0M | ||
| Q1 25 | $-92.5M | $-31.0M | ||
| Q4 24 | $191.1M | $-25.0M | ||
| Q3 24 | $215.1M | $-243.0M | ||
| Q2 24 | $168.6M | $-7.0M | ||
| Q1 24 | $-14.6M | $-15.0M |
| Q4 25 | 21.2% | -2.9% | ||
| Q3 25 | 5.1% | -0.5% | ||
| Q2 25 | -65.6% | — | ||
| Q1 25 | -6.2% | -2.1% | ||
| Q4 24 | 17.5% | -1.4% | ||
| Q3 24 | 24.7% | -1.9% | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 7.3% | -1.3% |
| Q4 25 | 17.0% | -3.1% | ||
| Q3 25 | 22.3% | -1.0% | ||
| Q2 25 | -68.7% | -0.6% | ||
| Q1 25 | -10.3% | -2.2% | ||
| Q4 24 | 17.6% | -1.5% | ||
| Q3 24 | 20.4% | -23.4% | ||
| Q2 24 | 16.5% | -0.8% | ||
| Q1 24 | -1.6% | -1.6% |
| Q4 25 | $3.34 | $-0.28 | ||
| Q3 25 | $4.08 | $-0.08 | ||
| Q2 25 | $-11.74 | $-0.05 | ||
| Q1 25 | $-1.52 | $-0.18 | ||
| Q4 24 | $2.97 | $-0.17 | ||
| Q3 24 | $3.42 | $-1.81 | ||
| Q2 24 | $2.49 | $-0.06 | ||
| Q1 24 | $-0.23 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $17.0M |
| Total DebtLower is stronger | $5.4B | $387.0M |
| Stockholders' EquityBook value | $4.3B | $1.5B |
| Total Assets | $11.7B | $3.3B |
| Debt / EquityLower = less leverage | 1.24× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $17.0M | ||
| Q3 25 | $1.3B | $25.0M | ||
| Q2 25 | $1.2B | $18.0M | ||
| Q1 25 | $1.9B | $16.0M | ||
| Q4 24 | $2.4B | $35.0M | ||
| Q3 24 | $2.2B | $55.0M | ||
| Q2 24 | $1.4B | $7.0M | ||
| Q1 24 | $1.4B | $7.0M |
| Q4 25 | $5.4B | $387.0M | ||
| Q3 25 | $5.4B | $387.0M | ||
| Q2 25 | $5.4B | $387.0M | ||
| Q1 25 | $5.4B | $387.0M | ||
| Q4 24 | $6.1B | $351.0M | ||
| Q3 24 | $6.1B | $352.0M | ||
| Q2 24 | $5.7B | $370.0M | ||
| Q1 24 | $5.7B | $351.0M |
| Q4 25 | $4.3B | $1.5B | ||
| Q3 25 | $4.0B | $1.6B | ||
| Q2 25 | $3.7B | $1.6B | ||
| Q1 25 | $4.2B | $1.6B | ||
| Q4 24 | $4.1B | $1.6B | ||
| Q3 24 | $4.2B | $1.7B | ||
| Q2 24 | $3.8B | $579.0M | ||
| Q1 24 | $3.7B | $582.0M |
| Q4 25 | $11.7B | $3.3B | ||
| Q3 25 | $11.4B | $3.2B | ||
| Q2 25 | $10.9B | $3.2B | ||
| Q1 25 | $11.5B | $3.3B | ||
| Q4 24 | $12.0B | $3.4B | ||
| Q3 24 | $12.3B | $3.4B | ||
| Q2 24 | $11.4B | $1.8B | ||
| Q1 24 | $11.3B | $1.8B |
| Q4 25 | 1.24× | 0.25× | ||
| Q3 25 | 1.35× | 0.24× | ||
| Q2 25 | 1.45× | 0.24× | ||
| Q1 25 | 1.29× | 0.24× | ||
| Q4 24 | 1.49× | 0.22× | ||
| Q3 24 | 1.47× | 0.21× | ||
| Q2 24 | 1.52× | 0.64× | ||
| Q1 24 | 1.54× | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $7.0M |
| Free Cash FlowOCF − Capex | $345.8M | $-9.0M |
| FCF MarginFCF / Revenue | 28.9% | -0.6% |
| Capex IntensityCapex / Revenue | 1.4% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $-8.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $7.0M | ||
| Q3 25 | $474.6M | $23.0M | ||
| Q2 25 | $88.9M | $23.0M | ||
| Q1 25 | $429.8M | $-2.0M | ||
| Q4 24 | $398.6M | $-7.0M | ||
| Q3 24 | $398.7M | $-7.0M | ||
| Q2 24 | $331.4M | $-5.0M | ||
| Q1 24 | $267.2M | $7.0M |
| Q4 25 | $345.8M | $-9.0M | ||
| Q3 25 | $459.4M | $9.0M | ||
| Q2 25 | $75.9M | $9.0M | ||
| Q1 25 | $415.9M | $-17.0M | ||
| Q4 24 | $385.3M | $-19.0M | ||
| Q3 24 | $388.0M | $-18.0M | ||
| Q2 24 | $324.3M | $-16.0M | ||
| Q1 24 | $260.3M | $-4.0M |
| Q4 25 | 28.9% | -0.6% | ||
| Q3 25 | 40.8% | 0.6% | ||
| Q2 25 | 7.3% | 0.6% | ||
| Q1 25 | 46.3% | -1.2% | ||
| Q4 24 | 35.4% | -1.1% | ||
| Q3 24 | 36.8% | -1.7% | ||
| Q2 24 | 31.7% | -1.7% | ||
| Q1 24 | 28.9% | -0.4% |
| Q4 25 | 1.4% | 1.1% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.2% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.2% | 0.7% | ||
| Q3 24 | 1.0% | 1.1% | ||
| Q2 24 | 0.7% | 1.2% | ||
| Q1 24 | 0.8% | 1.2% |
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
